LEI: 213800FLQUB9J289RU66
2 May 2024
BATM
Advanced Communications Limited
("BATM"
or "the Group")
BATM selected for a prestigious
EU-funded TB diagnostics programme
Collaboration with the
National Research Council of Italy (CNR)
towards development of an
advanced solution for the rapid diagnosis of TB
BATM (LSE: BVC; TASE: BVC), a leading provider of
real-time technologies for networking solutions and medical
laboratory systems, is pleased to announce that the Group
has been selected for a prestigious
programme, that is receiving funding from the
European Union, for the development of an advanced tuberculosis
("TB") diagnostics solution. The Group has also been awarded a
grant of €0.5m towards the initial 18 months of the programme with
the potential for additional funding to be awarded thereafter for
the next stage.
The Group was selected by the
National Research Council of Italy (Consiglio Nazionale delle
Ricerche) ("CNR") under a competitive process involving many
companies and after a lengthy and detailed verification phase to
participate in the programme alongside one of CNR's research
institutes, the Institute for System Analysis and Computer Science
(Istituto di Analisi dei Sistemi ed Informatica) ("IASI").
The Group's participation reflects its strategy to advance the BATM
diagnostics division through developing advanced molecular
diagnostics solutions for substantial infectious disease markets,
with the global diagnostics market for TB being worth over $2bn. It
is also demonstrative of the steps that the Group is taking to
drive long-term sustainable growth through investing in constant
innovation to maintain the diagnostics division's technological
edge.
The programme is for the development
of a diagnostics system, based on the Rolling Circle Amplification
("RCA") method, for the rapid identification of TB and multi-drug
resistant TB. This builds on the existing work of the BATM
diagnostics division for the development of a rapid, RCA-based
sample-to-answer diagnostic solution for TB and multi-drug
resistant TB. The programme is receiving funding from the
European Regional Development Fund via the Lazio Regional
Operational Program of the Lazio regional government.
Moti Nagar,
CEO of BATM, said: "Our selection by such an
esteemed institute as CNR for this important initiative is
testament to the recognition of our expertise in developing
advanced, market-leading diagnostic solutions. TB remains one of
the world's leading killer infectious diseases and a persistent
global health security threat. We are honoured to be contributing
to the development of a solution that through faster and more
accurate diagnosis will lead to significantly more effective
prevention and treatment and ultimately save lives. This reflects
our dedication to continued innovation to produce world-class
molecular diagnostics solutions in line with our strategy. We look
forward to working closely with our partners on this programme to
learn from them and leverage our collective strengths to make
significant advancements in this important field of medical
technology."
Enquiries
|
BATM Advanced
Communications
|
|
|
Moti Nagar, Chief Executive Officer
|
+972 9866
2525
|
|
Ran Noy, Chief Financial Officer
|
|
|
|
|
|
Shore
Capital
|
|
|
Mark Percy, Anita Ghanekar, James Thomas
(Corporate Advisory)
|
+44 20 7408 4050
|
|
|
|
|
Gracechurch
Group
|
|
|
Harry Chathli, Claire Norbury
|
+44 20 4582 3500
|
Forward-looking
statements
This document contains forward-looking statements. Those
statements reflect the current opinions, evaluations and
estimations of the Group's management, and are based on the current
data regarding the Group's business as is detailed in this document
and in the Group's periodical, interim and immediate reports. The
Group does not undertake any obligation or make any representation
that actual results and events will be in line with those
statements, and stresses that they may differ materially from those
statements, due to changes in the Group's business, market,
competition, demand for the Group's products or services, general
economic factors or other factors that can influence the Group's
business and results, due to the risk factors that are detailed in
the Group's Annual Report, and due to information and factors that
are currently unknown to the Group's management and that, if known,
would affect the management's opinions, evaluations or estimations.
The Group will report the actual results and events according to
its legal, accounting and regulatory obligations, and does not
undertake any other obligation to report them or their deviations
from the forward-looking statements, or to update any of the
forward-looking statements in this document or to report that it is
not valid anymore.